Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Total Current Liabilities (2016 - 2025)

Iradimed (IRMD) has disclosed Total Current Liabilities for 13 consecutive years, with $12.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 58.71% to $12.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.8 million, a 58.71% increase, with the full-year FY2024 number at $8.5 million, down 47.86% from a year prior.
  • Total Current Liabilities was $12.8 million for Q3 2025 at Iradimed, up from $8.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $16.3 million in Q4 2023 to a low of $4.6 million in Q1 2021.
  • A 5-year average of $7.9 million and a median of $7.6 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 90.88% in 2023, then tumbled 47.86% in 2024.
  • Iradimed's Total Current Liabilities stood at $6.8 million in 2021, then increased by 25.37% to $8.6 million in 2022, then skyrocketed by 90.88% to $16.3 million in 2023, then crashed by 47.86% to $8.5 million in 2024, then surged by 50.33% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Total Current Liabilities are $12.8 million (Q3 2025), $8.8 million (Q2 2025), and $8.5 million (Q1 2025).